Cue Biopharma, Inc. (CUE): Earnings per share for the last twelve months

Graphic logo of Cue Biopharma Inc. (CUE)

Cue Biopharma, Inc. (CUE) TTM EPS dynamics demonstrate volatility, with the -27.11 level serving as a critical mark. Growth is fueled by the success of CUE-101 and Immuno-STAT innovations. Data transparency from competent executives requires only funding optimization. Meanwhile, high biosynthesis costs and patent protection create a significant barrier for new entrants, strengthening the issuer's market position.

CUE Cue Biopharma Inc. Net earnings per share for the last 12 months (07/04/2022 - 11/16/2026)

Financial and market metric breakdowns for Cue Biopharma Inc. (CUE)

- stock price and consensus target price:
Basic company analysis:Cue Biopharma Inc. - CUE
Mass-produced product of Cue Biopharma

Earnings per share (EPS TTM) measures the portion of annual net income allocated to each security, excluding issuance fluctuations. This metric determines the actual efficiency of capitalizing development costs for immunotherapy drugs and the Immuno-STAT platform. By analyzing the trailing 12-month earnings trend, an investor can observe cash flow dynamics in real-time. This allows for an assessment of the financial stability of Cue Biopharma, Inc. (CUE) during periods of price consolidation. The long-term consensus warrants caution due to the specific nature of the biotechnology sector.

Analysis of competing companies

IBRX: Net earnings per share for the last 12 months|Earnings per share for the trailing year IMCR (Immunocore)|JANX: Net earnings per share (EPS TTM)|RCUS - Net earnings per share for the last four quarters|Earnings per share for the last twelve months zymeworks.com|Net earnings per share for the last 12 months tangotx.com (TNGX)|Earnings per share for the last twelve months Iovance Biotherapeutics Inc (IOVA)|Net earnings per share for the last 12 months Immatics Corp IMTX|Xencor Inc - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Compass Therapeutics Corp CMPX|REPL - Earnings per share for the last twelve months|LYEL (lyell.com) - Earnings per share for the last 12 months|Innate Pharma S.A (IPHA) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Pyxis Oncology, Inc. (PYXS)|Net earnings per share for the last 12 months CGEN|IOBT - Net earnings per share for the trailing year|Net earnings per share for the last 12 months STRO (Sutro Bio)|Earnings per share for the last four quarters INKT|Net earnings per share (EPS TTM) HOWL (Werewolf Therapeutics)|Earnings per share for the trailing year IMMX|alxoncology.com - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months PDS Biotechnology Corporation|Sonnet BioTherapeutics Holdings Inc. (SONN) - Earnings per share for the last twelve months|MAIA Biotechnology - Earnings per share for the trailing year|LIMN (liminatuspharma.com) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) lavatherapeutics.com|Earnings per share for the last twelve months NextCure (NXTC)|LPTX: Earnings per one share for the last 12 months|Intensity Therapeutics, Inc. - Net earnings per share for the last 12 months|Sensei Biotherapeutics (SNSE) - Net earnings per one share for the last twelve months|TOVX: Net earnings per share for the last 12 months|Net earnings per share for the trailing year Gritstone bio (GRTS)|KA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NexImmune, Inc. (NEXI)|Earnings per share for the last twelve months turnstonebio.com|Net earnings per share for the last 12 months Vaccinex, Inc. (VCNX)|Earnings per share for the last twelve months Harpoon Therapeutics (HARP)